Widespread and early myocardial gene expression by adeno-associated virus vector type 6 with a β-actin hybrid promoter

Shunsuke Kawamoto, Qun Shi, Yoshio Nitta, Jun Ichi Miyazaki, Margaret D. Allen

研究成果: Article査読

34 被引用数 (Scopus)

抄録

Gene therapy for acute cardiac events such as myocardial infarction requires early gene expression over an entire region of myocardium, which has not been possible using adeno-associated virus (AAV) vectors to date. Here we demonstrate marked improvement in the distribution and rapidity of gene expression in myocardium using the AAV pseudotype 6 (AAV6) vector, compared to the standard serotype 2 (AAV2) vector. An alkaline phosphatase (AP) reporter construct driven by the chicken β-actin promoter was packaged in either AAV6 or AAV2 capsids and delivered to rat hearts in vivo by direct injection. AP expression was evident in both AAV6 and AAV2 vector-treated hearts as early as 1 day after injection, but increased rapidly in AAV6 vector-treated hearts during the first 7 days. The amplitude of AP activity produced by the AAV6 vector was 5-fold greater than that produced by the equivalent AAV2 vector at both 3 and 7 days postinjection. Additionally, the AAV6 vector transduced a myocardial volume that was 10-fold larger than the AAV2 vector. These results indicate the significant potential of AAV6 serotype vectors for early gene expression and widespread regional transduction of myocardium, both auspicious results for in vivo applications in acute cardiac disease.

本文言語English
ページ(範囲)980-985
ページ数6
ジャーナルMolecular Therapy
11
6
DOI
出版ステータスPublished - 2005 6月
外部発表はい

ASJC Scopus subject areas

  • 分子医療
  • 分子生物学
  • 遺伝学
  • 薬理学
  • 創薬

フィンガープリント

「Widespread and early myocardial gene expression by adeno-associated virus vector type 6 with a β-actin hybrid promoter」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル